<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802958</url>
  </required_header>
  <id_info>
    <org_study_id>10216913</org_study_id>
    <nct_id>NCT00802958</nct_id>
  </id_info>
  <brief_title>Randomized Study to Compare the Bioavailability of Two Halobetasol Propionate 0.05% Topical Ointments</brief_title>
  <official_title>Bioequivalence of Two Halobetasol Propionate 0.05% Topical Ointments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the relative vasoconstrictive effects of test and
      reference Halobetasol Propionate 0.05% Ointment in healthy, female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vasoconstriction will be measured by the degree of skin blanching observed after treatment removal using a ChromaMeter</measure>
    <time_frame>Over the course of a day</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort Group 1</arm_group_label>
    <description>Subjects number 1 to 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort Group 2</arm_group_label>
    <description>Subjects number 31 to 56</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort Group 3</arm_group_label>
    <description>Subject Numbers 57 to 76</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Halobetasol Propionate 0.05% Ointment-Reference Product</intervention_name>
    <description>Small amount applied and evaluated over the course of a day</description>
    <arm_group_label>Cohort Group 1</arm_group_label>
    <arm_group_label>Cohort Group 2</arm_group_label>
    <arm_group_label>Cohort Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Halobetasol Propionate 0.05% Ointment-Test Product</intervention_name>
    <description>Small amount applied and evaluated over the course of a day</description>
    <arm_group_label>Cohort Group 1</arm_group_label>
    <arm_group_label>Cohort Group 2</arm_group_label>
    <arm_group_label>Cohort Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Community Volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-tobacco using female subjects, 18 to 50 years of age

          -  Demonstrated blanching response to Reference Drug

          -  Weight within +/- 20% from normal for height and weight for body frame

          -  Good health as determined by lack of clinically significant abnormalities in medical
             history and clinical assessment, as judged by the Investigator

          -  Signed and dated informed consent form which meets all criteria of current FDA
             regulations

        Exclusion Criteria:

          -  History of allergy to systemic or topical corticosteroids

          -  Presence of any skin condition or coloration that would interfere with the placement
             of test sites or the response or assessment of skin blanching

          -  Presence of medical condition requiring regular treatment with prescription drugs

          -  Drug or alcohol addiction requiring treatment in the past 12 months prior to dosing

          -  Use of any tobacco products in the 30 days prior to study dosing

          -  Use of any dermatological drug therapy on the flexor surface of the forearms within 30
             days of dosing

          -  Receipt of any drugs as part of a research study within 30 days prior to study dosing

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Halobetasol Propionate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Halobetasol</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

